Editorial: Kinase inhibitors in cancer therapy
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.1020297/full |
_version_ | 1828337475766976512 |
---|---|
author | Dharmendra Kumar Yadav |
author_facet | Dharmendra Kumar Yadav |
author_sort | Dharmendra Kumar Yadav |
collection | DOAJ |
first_indexed | 2024-04-13T22:15:44Z |
format | Article |
id | doaj.art-9a906ffd4b804aa88eec71cf8f890051 |
institution | Directory Open Access Journal |
issn | 2296-634X |
language | English |
last_indexed | 2024-04-13T22:15:44Z |
publishDate | 2022-10-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Cell and Developmental Biology |
spelling | doaj.art-9a906ffd4b804aa88eec71cf8f8900512022-12-22T02:27:33ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2022-10-011010.3389/fcell.2022.10202971020297Editorial: Kinase inhibitors in cancer therapyDharmendra Kumar Yadavhttps://www.frontiersin.org/articles/10.3389/fcell.2022.1020297/fullBax/Bcl-2kinase inhibitorsEGFR pathwayRAS-RAF-MEK-ERK pathwayRET = rearranged during transfection |
spellingShingle | Dharmendra Kumar Yadav Editorial: Kinase inhibitors in cancer therapy Frontiers in Cell and Developmental Biology Bax/Bcl-2 kinase inhibitors EGFR pathway RAS-RAF-MEK-ERK pathway RET = rearranged during transfection |
title | Editorial: Kinase inhibitors in cancer therapy |
title_full | Editorial: Kinase inhibitors in cancer therapy |
title_fullStr | Editorial: Kinase inhibitors in cancer therapy |
title_full_unstemmed | Editorial: Kinase inhibitors in cancer therapy |
title_short | Editorial: Kinase inhibitors in cancer therapy |
title_sort | editorial kinase inhibitors in cancer therapy |
topic | Bax/Bcl-2 kinase inhibitors EGFR pathway RAS-RAF-MEK-ERK pathway RET = rearranged during transfection |
url | https://www.frontiersin.org/articles/10.3389/fcell.2022.1020297/full |
work_keys_str_mv | AT dharmendrakumaryadav editorialkinaseinhibitorsincancertherapy |